Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

51.61 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Dec 23, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch ↗

November 12, 2025

Eli Lilly to drop CVS Health's drug benefit plan and move to Rightway in 2026 as Novo Nordisk cuts Wegovy prices in India to defend market share.

Via Benzinga

Why Metsera's Share Price Is Plummeting This Week ↗

November 12, 2025

The biotech start-up's stock had been rising rapidly in 2025.

Via The Motley Fool

‘Somebody Knows Something:’ Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenarios ↗

November 11, 2025

Via Stocktwits

AMD, Oklo, AppLovin Corp, Viking Therapeutics And Novo Nordisk: Why These 5 Stocks Are On Investors' Radars Today ↗

November 11, 2025

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 inching up 0.2% to 6,846.61.

Via Benzinga

Topics Stocks

Trump Announces Deals With Eli Lilly, Novo Nordisk To Lower Obesity Drug Prices ↗

November 06, 2025

Via Stocktwits

Topics Government

Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India ↗

November 11, 2025

Novo Nordisk shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 11, 2025

Via Benzinga

Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market? ↗

November 11, 2025

Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.

Via The Motley Fool

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

November 10, 2025

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion ↗

November 10, 2025

The final bid, at $10 billion, is expected to wrap up after Nov. 13 with the next shareholders' vote.

Via Investor's Business Daily

Topics Initial Public Offering

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

November 10, 2025

Via Benzinga

Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith ↗

November 09, 2025

Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.

Via Stocktwits

Huge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump ↗

November 09, 2025

The companies announced a huge deal that will have implications for investors.

Via The Motley Fool

Topics World Trade

Should You Buy Novo Nordisk After the Huge Investor Update? ↗

November 09, 2025

Pharma companies are under pressure to lower prices in the U.S.

Via The Motley Fool

Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock? ↗

November 09, 2025

The company continues to have a strong growth outlook ahead.

Via The Motley Fool

Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors. ↗

November 08, 2025

Weight loss drugs generated about $10 billion for Lilly in the most recent quarter.

Via The Motley Fool

Topics Government

Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance ↗

November 08, 2025

Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."

Via Benzinga

Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy ↗

November 07, 2025

Via Benzinga

Why Novo Nordisk Stock Is Sinking This Week ↗

November 07, 2025

The global drugmaker is facing some headwinds related to tough competition.

Via The Motley Fool

Topics Government World Trade

Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment ↗

November 07, 2025

Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment.

Via Benzinga

FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included ↗

November 07, 2025

FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs.

Via Benzinga

The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗

November 07, 2025

The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.

Via Investor's Business Daily

Topics Government

Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced ↗

November 06, 2025

Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage.

Via Stocktwits

Topics Government World Trade

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts ↗

November 06, 2025

Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026.

Via Benzinga

Topics Government

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as...

Via TokenRing AI

Topics Artificial Intelligence Climate Change Intellectual Property

Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx ↗

November 06, 2025

The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026.

Via Benzinga

Topics Government

Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know. ↗

November 06, 2025

Is the fourth time the charm for this Danish pharmaceutical giant?

Via The Motley Fool

Topics Earnings

Trump Slashes Weight-Loss Drug Prices By Up To 74% In Deal With Lilly, Novo ↗

November 06, 2025

The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their obesity drugs.

Via Investor's Business Daily

Topics Government

Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits ↗

November 06, 2025

Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for new doses.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today